IM Cannabis Earnings Call Transcripts
Fiscal Year 2025
-
Q1 2025 saw a return to profitability, driven by a 569% revenue surge in Germany and significant cost reductions, offsetting declines in Israel. Gross margin improved 87% year-over-year, with net profit reaching EUR 0.2 million and positive adjusted EBITDA.
Fiscal Year 2024
-
German revenue surged post-legalization, driving 11% annual growth and a return to positive Adjusted EBITDA in Q4. Cost reductions and supply chain integration improved efficiency, while inventory write-offs impacted margins. Focus remains on German expansion for 2025.
-
Q3 2024 saw strong revenue growth in Germany, offsetting declines in Israel due to regulatory and market challenges. Operating efficiency improved, with a focus on supply chain integration and premium products, setting the stage for accelerated German growth in 2025.
-
Q2 2024 saw a 200% sales surge in Germany post-legalization, driving 11.7% revenue growth year-over-year. Gross margin dropped due to inventory actions in Israel, but German margins remain strong at 40%. Strategic focus is now on German expansion and premium Israeli products.